
    
      LB80380, an oral prodrug, is a promising candidate nucleotide analogue with antiviral
      activity against wild-type hepatitis B virus (HBV). LB80380 is undergoing clinical
      development by LG Life Sciences for use in the treatment of chronic HBV infection.

      This study is an extension study of the Phase IIb (Protocol No. LG-BVCL007), the treatment
      period of this study is 48-week with 24-week of follow-up period
    
  